Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: November 30, 2022 Report Code: GDGMDHC22405IDB-ST

Select Item

Multiple Sclerosis Pipeline Drugs Development Market Report Overview

Multiple sclerosis (MS) is a potentially debilitating disease in which the body’s immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech.

The Multiple Sclerosis Drugs pipeline drugs market research report provides comprehensive information on the therapeutics under development for Multiple Sclerosis Drugs, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Multiple Sclerosis Drugs and features dormant and discontinued projects.

Key Targets Tyrosine Protein Kinase BTK, Nuclear Factor Erythroid 2 Related Factor 2, Cannabinoid Receptor 1, and Cannabinoid Receptor 2 among others
Key Mechanisms of Action Tyrosine Protein Kinase BTK Inhibitor, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Cannabinoid Receptor 1 Agonist, and Cannabinoid Receptor 2 Agonist among others
Key Routes of Administration Oral, Intravenous, Subcutaneous, Parenteral, Intramuscular, Intrathecal, Inhalational, Transdermal, Topical, and Intraarticular among others
Key Molecule Types Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, and Fusion Protein among others
Key Companies Biogen Inc, Novartis AG, Sanofi, Travecta Therapeutics Pte Ltd, and NervGen Pharma Corp, and among others
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Multiple Sclerosis Drugs Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Multiple Sclerosis Drugs pipeline drugs market are Tyrosine Protein Kinase BTK, Nuclear Factor Erythroid 2 Related Factor 2, Cannabinoid Receptor 1, and Cannabinoid Receptor 2 among others.  Tyrosine Protein Kinase BTK led this segment of the Multiple Sclerosis Drugs pipeline drugs market in 2022.

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis by Targets, 2022 (%)

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis, by TargetsFor more Multiple Sclerosis Drugs pipeline drugs market target insights, download a free report sample

Multiple Sclerosis Drugs Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Multiple Sclerosis Drugs pipeline drugs market are Tyrosine Protein Kinase BTK Inhibitor, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Cannabinoid Receptor 1 Agonist, and Cannabinoid Receptor 2 Agonist among others.  Tyrosine Protein Kinase BTK Inhibitor led the Multiple Sclerosis Drugs pipeline drugs market in terms of MoA in 2022.

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more mechanisms of action insights into the Multiple Sclerosis Drugs pipeline drugs market, download a free report sample

Multiple Sclerosis Drugs Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Multiple Sclerosis Drugs pipeline drugs market are oral, intravenous, subcutaneous, parenteral, intramuscular, intrathecal, inhalational, transdermal, topical, and intraarticular among others. In 2022, the most prominent RoA in the Multiple Sclerosis Drugs pipeline drugs market was oral.

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the Multiple Sclerosis Drugs pipeline drugs market, download a free report sample

Multiple Sclerosis Drugs Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Multiple Sclerosis Drugs pipeline drugs market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, and fusion protein among others. Small molecule led the Multiple Sclerosis Drugs pipeline drugs market in terms of molecule types in 2022.

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule-type insights into the Multiple Sclerosis Drugs pipeline drugs market, download a free report sample

Multiple Sclerosis Drugs Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Multiple Sclerosis Drugs pipeline drugs market are Biogen Inc, Novartis AG, Sanofi, Travecta Therapeutics Pte Ltd, and NervGen Pharma Corp, and among others. Biogen Inc had the highest number of products under development in 2022.

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis by Companies, 2022 (%)

Multiple Sclerosis Drugs Pipeline Drugs Market Analysis, by CompaniesTo know more about the Multiple Sclerosis Drugs pipeline drugs market companies, download a free report sample

Key Segments Covered in this Report

Multiple Sclerosis Drugs Pipeline Drugs Target Outlook (Number of Drugs, 2022)

  • Tyrosine Protein Kinase BTK
  • Nuclear Factor Erythroid 2 Related Factor 2
  • Cannabinoid Receptor 1
  • Cannabinoid Receptor 2
  • Others

Multiple Sclerosis Drugs Pipeline Drugs MoA Outlook (Number of Drugs, 2022)

  • Tyrosine Protein Kinase BTK Inhibitor
  • Nuclear Factor Erythroid 2 Related Factor 2 Activator
  • Cannabinoid Receptor 1 Agonist
  • Cannabinoid Receptor 2
  • Others

Multiple Sclerosis Drugs Pipeline Drugs RoA Outlook (Number of Drugs, 2022)

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Others

Multiple Sclerosis Drugs Pipeline Drugs Molecule Type Outlook (Number of Drugs, 2022)

  • Small Molecule
  • Monoclonal Antibody
  • Cell Therapy
  • Synthetic Peptide
  • Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis Drugs.

  • The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis Drugs by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Multiple Sclerosis Drugs therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Multiple Sclerosis Drugs therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for Multiple Sclerosis Drugs

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis Drugs.

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding the Multiple Sclerosis Drugs pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

4D Pharma Plc
AB Science SA
Abata Therapeutics
AbbVie Inc
Abion Inc
Abivax SA
Aditxt Inc
Aequus Pharmaceuticals Inc
Affectis Pharmaceuticals AG
AgoneX Biopharmaceuticals Inc
Ahead Therapeutics SL
Akaal Pharma Pty Ltd
Alector Inc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Alpine Immune Sciences Inc
Altheia Science SRL
Amarna Therapeutics BV
Amgen Inc
Amylyx Pharmaceuticals Inc
Ankar Pharma SL
Anokion SA
Antisense Therapeutics Ltd
AnTolRx Inc
Apaxen
Aphios Corp
Apimeds Inc
AptaTargets SL
Artax Biopharma Inc
ArunA Bio Inc
Asdera LLC
Aslan Pharmaceuticals Ltd
Atara Biotherapeutics Inc
Athersys Inc
Autobahn Therapeutics Inc
Autoimmunity Biologic Solutions Inc
Avicanna Inc
Avidea Technologies Inc
Avotres Inc
Axxam SpA
Barricade Therapeutics Corp
Bayer AG
Baylx Inc
BioApex sro
Bioasis Technologies Inc
Biocad
Biocon Ltd
Biocure Technology Inc
Biogen Inc
BioIncept LLC
Bionorica SE
BioNTech SE
BioSyngen Pte Ltd
Biovista Inc
BioXpress Therapeutics SA
Bisichem Co Ltd
Bolder Biotechnology Inc
Boston Pharmaceuticals Inc
BoYen Therapeutics Inc
BrainStorm Cell Therapeutics Inc
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
BTB Pharma AB
CarthroniX Inc
CavoGene LifeSciences
Cellerys AG
Cellix Bio Pvt Ltd
Cerion LLC
CGeneTech (Suzhou China) Co Ltd
Cinnagen Co
Clene Inc
Complement Pharma BV
Compugen Ltd
Convelo Therapeutics Inc
Cresence AS
CSPC Pharmaceutical Group Ltd
CuraVac Inc
CuroNZ Ltd
Cytodyn Inc
Cyxone AB
DC4U BV
Denali Therapeutics Inc
DiNonA Inc
Disarm Therapeutics Inc
Dr. Reddy's Laboratories Ltd
Dragonfly Therapeutics Inc
Dualogics Corp
EA Pharma Co Ltd
Eikonoklastes Therapeutics Inc
Eldrug SA
Eli Lilly and Co
ENCEFA
Endece LLC
Epitracker Inc
Erganeo
Ever Supreme Bio Technology Co Ltd
Evgen Pharma Plc
Evopoint Bioscience Co Ltd
F. Hoffmann-La Roche Ltd
f5 Therapeutics Inc
Farmacija d.o.o. Tuzla
FibroGenesis LLC
Find Therapeutics Inc
Fortuna Fix Inc
Frequency Therapeutics Inc
FSD Pharma Inc
GABA Therapeutics Inc
Galmed Pharmaceuticals Ltd
Genentech USA Inc
Generos Biomedical Technology (Hangzhou) Co Ltd
Genervon Biopharmaceuticals LLC
GeNeuro SA
Gilead Sciences Inc
Glialogix Inc
Glixogen Therapeutics
Gossamer Bio Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Lupeng Pharmaceutical Co Ltd
H. Lundbeck AS
Hope Biosciences LLC
HuniLife Biotechnology Inc
iCell Gene Therapeutics LLC
Idorsia Pharmaceutical Ltd
Iltoo Pharma
ImCyse SA
Immune Response BioPharma Inc
Immungenetics AG
Immunic Inc
ImmunoBiome Inc
ImmunoChem Therapeutics LLC
Immunwork Inc
ImmusanT Inc
Immutep Ltd
Impetis Biosciences Ltd
Imstem Biotechnology Inc
InFlectis BioScience SAS
Inmagene Biopharmaceuticals Ltd
Inmune Bio Inc
InnoBioscience LLC
InnoCare Pharma Ltd
Innovimmune Biotherapeutics Inc
Io Therapeutics Inc
ISOThrive Inc
Istesso Ltd
J2H Biotech
Johnson & Johnson
JSR Life Sciences LLC
Jura Bio Inc
Jyant Technologies Inc
Karo Pharma AB
Klogene Therapeutics Inc
Kogenix Therapeutics Inc
Kymera Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Landos Biopharma Inc
Lead Discovery Center GmbH
Leukosight Inc
LFB SA
LIFNano Rx Ltd
Lys Therapeutics SAS
Mabion SA
MAKScientific LLC
Malachite Innovations Inc
Mapi Pharma Ltd
Maruho Co Ltd
MD Healthcare Inc
Med-Life Discoveries LP
MedAnnex Ltd
MedDay SA
Medsenic SAS
Mercaptor Discoveries Inc
Merck & Co Inc
Merck KGaA
MetiMedi Pharmaceuticals Co Ltd
MetrioPharm AG
Millennium Pharmaceuticals Inc
Mitochon Pharmaceuticals Inc
Mitotech SA
Mitsubishi Tanabe Pharma Corp
MMJ International Holdings Corp
Mochida Pharmaceutical Co Ltd
Moderna Inc
Molecules For Health Inc
MorphoSys AG
MyMD Pharmaceuticals Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
NervGen Pharma Corp
Neuraly Inc
Neuren Pharmaceuticals Ltd
Neuro Vigor LLC
NeuroGenesis Ltd
NeuroScientific Biopharmaceuticals Ltd
New World Laboratories Inc
Novartis AG
Novellus Therapeutics Ltd
Novoron Bioscience Inc
Numab Therapeutics AG
Oculis SA
Omeros Corp
Oncodesign SA
Op-T-Mune Inc
Orion Biotechnology Canada Ltd
Orpheris Inc
Oryzon Genomics SA
OSE Immunotherapeutics SA
Ossianix Inc
Pahan Therapeutics
Palisade Bio, Inc
Pangen Biotech Inc
Par'Immune SAS
Parkside Scientific Inc
Parvus Therapeutics Inc
Pasithea Therapeutics Corp
PB Immune Therapeutics Co Ltd
PharmatrophiX Inc
PharmCADD Co Ltd
Pheno Therapeutics Ltd
Pipeline Therapeutics Inc
Polpharma Biologics SA
PolTREG SA
PrecisemAb Biotech Co Ltd
Principia Biopharma Inc
Progenitor Therapeutics Ltd
ProNoxis AB
Protheragen Inc
Provid Pharmaceuticals Inc
Q Therapeutics Inc
Quimatryx SL
ReceptoPharm Inc
RegeneRx Biopharmaceuticals Inc
Rekover Therapeutics Ltd
RemeGen Co Ltd
ReNetX Bio
ReNeuroGen LLC
Resverlogix Corp
Revalesio Corp
Reven Holdings Inc
Rewind Therapeutics NV
Rigel Pharmaceuticals Inc
Riptide Bioscience Inc
Sana Biotechnology Inc
SanBio Co Ltd
Sangamo Therapeutics Inc
Sanofi
Sansho Co Ltd
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
Sareum Holdings Plc
Scientus Pharma Inc
Score Pharma Inc
Senda Biosciences Inc
Senzer Ltd
Serenity Bioworks Inc
Shanghai Pharmaceutical Group Co Ltd
Shanxi Zhendong Pharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Silo Pharma Inc
SinoCelltech Group Ltd
Sironax Ltd
Sorrento Therapeutics Inc
Statera Biopharma Inc
Stem Cell Medicine Ltd
Sujana Biotech, LLC
Suzhou Connect Biopharmaceuticals Ltd
SynAct Pharma AB
Synaptogenix Inc
Takeda Pharmaceutical Co Ltd
Tavanta Therapeutics Inc
Teikoku Pharma USA Inc
TeraImmune Inc
Tetra Therapeutics
Tevogen Bio Inc
Theratome Bio Inc
Therini Bio Inc
Tiziana Life Sciences Plc
TolerogenixX GmbH
Tonix Pharmaceuticals Holding Corp
Transparency Life Sciences LLC
Travecta Therapeutics Pte Ltd
Trio Medicines Ltd
Twinpigbiolab Co Ltd
TwotoBiotech Ltd
UBI Pharma Inc
UCB SA
USA Elixiria Biotech Inc
Vaccinex Inc
Vascular Biogenics Ltd
Vertex Pharmaceuticals Inc
Vir Biotechnology Inc
Virogenomics BioDevelopment Inc
Virtici LLC
Vitalis LLC
Vitro Biopharma Inc
Voronoi Group
West Lake Biomedical Technology (Hangzhou) Co Ltd
Worg Pharmaceuticals Hangzhou Co Ltd
Xalud Therapeutics Inc
Xonovo Inc
XOStem Biosciences Ltd
Zydus Lifesciences Ltd
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Multiple Sclerosis – Overview

Multiple Sclerosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Multiple Sclerosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Multiple Sclerosis – Companies Involved in Therapeutics Development

Multiple Sclerosis – Drug Profiles

Multiple Sclerosis – Dormant Projects

Multiple Sclerosis – Discontinued Products

Multiple Sclerosis – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Multiple Sclerosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Multiple Sclerosis – Dormant Projects, 2022

Multiple Sclerosis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Multiple Sclerosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more